Revah joins Genethon as ceo

Genethon, a biotherapy research centre created by the French Muscular Dystrophy Association (AFM), has appointed Frederic Revah as chief executive.

Genethon, a biotherapy research centre created by the French Muscular Dystrophy Association (AFM), has appointed Frederic Revah as chief executive.

Revah brings more than 20 years' experience in the pharmaceutical and biotech industries and academic research to the job.

Immediately prior to joining Genethon, Revah had been chief executive of the oncology start-up Sepal Pharma since 2008. Before that, he was vice president, Drug Discovery, and chief scientific officer of Cerep from 1999 to 2007 and chief executive of its oncology subsidiary.




You may also like

Research & Development

Gene therapy centre to open in France next year

Genethon BioProd to produce 20 clinical batches of gene therapy products a year
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Manufacturing

Anton Paar expands Litesizer DIA Series with new models

Introducing affordable and advanced solutions for particle analysis
Manufacturing

Triple your efficiency with the new DrySyn Vortex

Boost productivity with temperature-controlled parallel reactions
Manufacturing

Five critical design elements for Pelton wheel turbine flowmeters

Titan Enterprises outlines the factors for cost-effective and reliable low-flow measurement
Research & Development

Roche acquires clinical-stage biopharmaceutical company Poseida Therapeutics

Through the merger, Roche will acquire Poseida's allogeneic CAR-T cell therapy portfolio, including pre-clinical and clinical-stage iterations for a range of conditions
Subscribe now